LifeMD (NASDAQ:LFMD) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of LifeMD (NASDAQ:LFMD) from a hold rating to a sell rating in a report released on Saturday.

Several other brokerages have also issued reports on LFMD. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of LifeMD in a research report on Tuesday, May 26th. Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of LifeMD in a research note on Monday, May 4th. Finally, UBS Group restated a “buy” rating on shares of LifeMD in a research note on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.14.

LifeMD Stock Performance

LifeMD stock opened at $4.32 on Friday. LifeMD has a one year low of $2.56 and a one year high of $12.72. The stock has a fifty day moving average of $4.55 and a 200 day moving average of $3.98. The stock has a market cap of $208.92 million, a PE ratio of 86.42 and a beta of 1.99.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The firm had revenue of $50.16 million during the quarter, compared to analysts’ expectations of $48.84 million. As a group, sell-side analysts predict that LifeMD will post -0.37 EPS for the current fiscal year.

Institutional Trading of LifeMD

Several institutional investors and hedge funds have recently added to or reduced their stakes in LFMD. Federated Hermes Inc. boosted its stake in LifeMD by 278.1% in the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock worth $3,343,000 after purchasing an additional 721,018 shares during the period. Prescott Group Capital Management L.L.C. bought a new stake in shares of LifeMD during the fourth quarter valued at approximately $2,344,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of LifeMD by 1,767.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock worth $5,924,000 after buying an additional 411,651 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of LifeMD by 581.2% in the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after buying an additional 352,004 shares in the last quarter. Finally, Whetstone Capital Advisors LLC lifted its holdings in shares of LifeMD by 89.6% in the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock worth $2,397,000 after buying an additional 332,269 shares in the last quarter. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.